Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.41 |
| ▸ | METAP2 | P50579 | 8/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23516094 | 0.96 | METAP2 (0.43) | METAP2ROCK2CHEK1MAP4K4PRKACA | |
| SCHEMBL23516097 | 0.94 | MAPK14 (0.41) | MAPK14METAP2ROCK2CDC7MAP4K4 | |
| SCHEMBL23516515 | 0.89 | METAP2 (0.43) | MAPK14METAP2CHEK1GSK3B | |
| SCHEMBL23515988 | 0.89 | MEN1 (0.36) | MAPK14DUSP3 | |
| SCHEMBL23516095 | 0.89 | ROCK2 (0.39) | MAPK14METAP2ROCK2CHEK1CDC7 | |
| SCHEMBL23515907 | 0.86 | DUSP3 (0.42) | MAPK14ROCK2DUSP3 | |
| SCHEMBL23516532 | 0.85 | METAP2 (0.45) | MAPK14METAP2IRAK4 | |
| SCHEMBL23516352 | 0.85 | HSPA1A (0.41) | MAPK14METAP2 | |
| SCHEMBL23515911 | 0.85 | CHEK1 (0.39) | CHEK1 | |
| SCHEMBL23515966 | 0.84 | METAP2 (0.46) | MAPK14METAP2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11276825-B2 | Organic molecules for use in organic devices | CYNORA GMBH (DE) | 2022-03-15 | — | — | US | disclosed |
| US-20210184134-A1 | ORGANIC MOLECULES FOR USE IN ORGANIC DEVICES | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210184134-A1 | ORGANIC MOLECULES FOR USE IN ORGANIC DEVICES | CHRM1, C1S, DNMT3L | MAPK14 2770/4885METAP2 3053/4885ROCK2 747/4885 |
| US-11276825-B2 | Organic molecules for use in organic devices | AOX1, OR10J3, L1CAM | MAPK14 3910/4885METAP2 3608/4885ROCK2 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.